Peripherally inserted central catheters (PICCs) are great for keeping patients out of the hospital, but potentially dangerous due to thrombi forming on and within the surface of these devices. All sorts of coatings exist for PICCS to prevent blood coagulation, including those containing anticoagulants like heparin. But the problem persists.
AngioDynamics has received FDA clearance for the BioFlo PICC that takes advantage of Endexo polymer technology to help prevent clot formation. PICC coatings are typically either applied to the surface or impregnated into pores specially formed during manufacturing. The Endexo polymer within the BioFlo is an integral part of the catheter material itself, so it remains permanently on the PICC throughout its lifetime while offering anticoagulant properties similar to devices that elute heparin, according to pre-clinical studies.
From the announcement:
In vitro blood loop model test results show the BioFlo PICC has 87% less thrombus accumulation on its surface on average compared to commonly used PICCs based on platelet count. In addition, side-by-side in vivo test results demonstrate substantially equivalent thromboresistant characteristics as a heparin coated vascular access catheter.* Available with PASV Valve Technology, it is the first catheter that combines all of these properties with AngioDynamics’ patented valve designed to automatically resist backflow and reduce blood reflux on the inside of the catheter.